Clinical Trial Update: Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada

View source ↗

Summary

This clinical trial update describes the impact of tildrakizumab on patient-reported outcomes in adults with moderate-to-severe psoriasis in Canada; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Ilumya (tildrakizumab)

Snippet

Sponsor: Chronicle Academy | Conditions: Psoriasis (PsO), Moderate to Severe Psoriasis | Status: RECRUITING